Black Diamond Therapeutic...

1.50
-0.08 (-5.06%)
At close: Apr 03, 2025, 3:59 PM
1.47
-2.33%
Pre-market: Apr 04, 2025, 05:02 AM EDT

Black Diamond Therapeutics Statistics

Share Statistics

Black Diamond Therapeutics has 56.66M shares outstanding. The number of shares has increased by 0.73% in one year.

Shares Outstanding 56.66M
Shares Change (YoY) 0.73%
Shares Change (QoQ) 0.14%
Owned by Institutions (%) 84.78%
Shares Floating 43.14M
Failed to Deliver (FTD) Shares 7.34K
FTD / Avg. Volume 0.21%

Short Selling Information

The latest short interest is 7.49M, so 13.24% of the outstanding shares have been sold short.

Short Interest 7.49M
Short % of Shares Out 13.24%
Short % of Float 17.46%
Short Ratio (days to cover) 6.59

Valuation Ratios

The PE ratio is -1.69 and the forward PE ratio is -1.97. Black Diamond Therapeutics's PEG ratio is 0.05.

PE Ratio -1.69
Forward PE -1.97
PS Ratio 0
Forward PS 0.4
PB Ratio 1.41
P/FCF Ratio -1.89
PEG Ratio 0.05
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Black Diamond Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.23.

Current Ratio 4.92
Quick Ratio 4.92
Debt / Equity 0.23
Debt / EBITDA -0.24
Debt / FCF -0.3
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-2.9M
Employee Count 24
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -70.65% in the last 52 weeks. The beta is 2.82, so Black Diamond Therapeutics's price volatility has been higher than the market average.

Beta 2.82
52-Week Price Change -70.65%
50-Day Moving Average 2.04
200-Day Moving Average 3.53
Relative Strength Index (RSI) 37.27
Average Volume (20 Days) 3.42M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -78.78M
Net Income -69.68M
EBITDA -78.78M
EBIT n/a
Earnings Per Share (EPS) -1.27
Full Income Statement

Balance Sheet

The company has 36.44M in cash and 18.78M in debt, giving a net cash position of 17.66M.

Cash & Cash Equivalents 36.44M
Total Debt 18.78M
Net Cash 17.66M
Retained Earnings -487.11M
Total Assets 122.64M
Working Capital 80.6M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -62.3M and capital expenditures 0, giving a free cash flow of -62.3M.

Operating Cash Flow -62.3M
Capital Expenditures 0
Free Cash Flow -62.3M
FCF Per Share -1.13
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BDTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BDTX is $15, which is 900% higher than the current price. The consensus rating is "Buy".

Price Target $15
Price Target Difference 900%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -5.61
Piotroski F-Score 1